ES2572355R1 - Combinación de aad para uso en el tratamiento del vhc - Google Patents

Combinación de aad para uso en el tratamiento del vhc Download PDF

Info

Publication number
ES2572355R1
ES2572355R1 ES201431521A ES201431521A ES2572355R1 ES 2572355 R1 ES2572355 R1 ES 2572355R1 ES 201431521 A ES201431521 A ES 201431521A ES 201431521 A ES201431521 A ES 201431521A ES 2572355 R1 ES2572355 R1 ES 2572355R1
Authority
ES
Spain
Prior art keywords
combination
treatment
adb
hcv
antiviral agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201431521A
Other languages
English (en)
Other versions
ES2572355A2 (es
ES2572355B1 (es
Inventor
M. BERNSTEIN Barry
M. MENON Rajeev
Amit KHATRI
Sven MENSING
Sandeep DUTTA
E. COHEN Daniel
J. PODSADECKI Thomas
C. BRUN Scott
M. AWNI Walid
O. DUMAS Emily
E. KLEIN Cheri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of ES2572355A2 publication Critical patent/ES2572355A2/es
Publication of ES2572355R1 publication Critical patent/ES2572355R1/es
Application granted granted Critical
Publication of ES2572355B1 publication Critical patent/ES2572355B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinación de AAD para uso en el tratamiento del VHC.#La presente invención presenta combinaciones de agentes antivirales para uso en terapias sin interferón y ribavirina en el tratamiento de VHC. Preferentemente, el tratamiento es durante un tiempo de tratamiento corto, tal como no más de 12 semanas. En un aspecto, el uso de las combinaciones de agentes antivirales en las terapias comprende administrar al menos dos agentes antivirales de acción directa sin interferón y ni ribavirina a un sujeto con infección por VHC.
ES201431521A 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc Withdrawn - After Issue ES2572355B1 (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201161055036P 2011-10-21 2011-10-21
US61/55036 2011-10-21
US201161056217P 2011-11-21 2011-11-21
US61/56217 2011-11-21
US201261058719P 2012-01-17 2012-01-17
US61/58719 2012-01-17
US201261060046P 2012-02-17 2012-02-17
US61/60046 2012-02-17
US201261061988P 2012-04-03 2012-04-03
US61/61988 2012-04-03
US201261065625P 2012-06-06 2012-06-06
US61/65625 2012-06-06
US201261071179P 2012-10-10 2012-10-10
US61/71179 2012-10-10

Publications (3)

Publication Number Publication Date
ES2572355A2 ES2572355A2 (es) 2016-05-31
ES2572355R1 true ES2572355R1 (es) 2016-11-03
ES2572355B1 ES2572355B1 (es) 2017-08-24

Family

ID=52465028

Family Applications (3)

Application Number Title Priority Date Filing Date
ES201431520A Withdrawn - After Issue ES2572330B1 (es) 2011-10-21 2012-10-19 Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc
ES201490005A Expired - Fee Related ES2529144B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc
ES201431521A Withdrawn - After Issue ES2572355B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES201431520A Withdrawn - After Issue ES2572330B1 (es) 2011-10-21 2012-10-19 Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc
ES201490005A Expired - Fee Related ES2529144B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc

Country Status (1)

Country Link
ES (3) ES2572330B1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32699A (es) * 2009-06-11 2010-12-31 Abbott Lab Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados
CN104771364B (zh) * 2010-03-10 2018-05-25 艾伯维巴哈马有限公司 固体组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAZWINSKI ALISON B et al. Direct-acting antiviral medications for chronic hepatitis C virus infection..Gastroenterology & hepatology United States Mar 2011 00/03/2011 VOL: 7 No: 3 Pags: 154 - 162 ISSN 1554-7914 (Print) Doi: pubmed:21528041, página, 160 ultimo párrafo y 161 *
LOK ANNA S et al. COMBINATION THERAPY WITH BMS-790052 AND BMS-650032 ALONE OR WITH PEGIFN/RBV RESULTS IN UNDETECTABLE HCV RNA THROUGH 12 WEEKS OF THERAPY IN HCV GENOTYPE 1 NULL RESPONDERS.Hepatology, 20101001 01/10/2010 VOL: 52 No: 4, Suppl Pags: 877A ISSN 0270-9139, resumen *

Also Published As

Publication number Publication date
ES2572355A2 (es) 2016-05-31
ES2529144B1 (es) 2015-10-26
ES2529144R1 (es) 2015-03-10
ES2529144A2 (es) 2015-02-17
ES2572330R1 (es) 2016-11-03
ES2572355B1 (es) 2017-08-24
ES2572330B1 (es) 2017-08-24
ES2572330A2 (es) 2016-05-31

Similar Documents

Publication Publication Date Title
ES2572329R1 (es) Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
EA201591702A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
DOP2014000067A (es) Tratamiento combinado (por ejemplo con abt-072 o abt-333) de agentes antivirales de acción directa (daas) para uso en el tratamiento de hcv
CR20150199A (es) Análogos de 2´-cloro nucleósido para infección por vhc
CL2016001509A1 (es) Formas cristalinas de los análogos de sofosbuvir antivirales
ECSP14013315A (es) Inhibidores de aplicación viral
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
MX2018000240A (es) Metodos para tratar el vhc.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
CO2017005759A2 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
CR20120166A (es) Composiciones y productos antimicrobianos
ES2572355R1 (es) Combinación de aad para uso en el tratamiento del vhc
EA201490963A1 (ru) Новые производные гемина с антибактериальной и противовирусной активностью
NZ602552A (en) Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais
Skilton et al. Needling: a treatment option for recalcitrant verrucae pedis.
CL2013002914A1 (es) Uso de alisporivir en combinación con el estándar de atención: interferón/ribavirina para preparar un medicamento útil en el tratamiento de hepatitis c (hcv), genotipo 1.
EA201491652A1 (ru) Средство для лечения вирусного гепатита с
CL2013000210A1 (es) Compuestos derivados de tiofeno 2,3,5 trisustituidos; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento de un trastorno o enfermedad en un sujeto causado o asociado con una infeccion por vhc, tales como cirrosis hepatica, carcinoma hepatocelular, entre otras.
AR084049A1 (es) Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2572355

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20170824

FA2A Application withdrawn

Effective date: 20180212